АNTIMETASTATIC EFFECT OF B. SUBTILIS IMV B-7724 LECTIN OBSERVED IN LEWIS LUNG CARCINOMA MODEL

Authors

  • N.I. Fedosova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • T.V. Symchych R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • N.L. Cheremshenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • A.V. Chumak R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • E.V. Koval R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • O.M. Karaman R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • I.M. Voyeykova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17914

Keywords:

antimetastatic effect, antitumor effect, B. subtilis IMV B-7724 lectin, Lewis lung carcinoma

Abstract

Aim: To study the antitumor and antimetastatic effects of B. subtilis IMV B-7724 lectin used in neoadjuvant and adjuvant settings in vivo. Materials and Methods: Studies were performed on C57Bl/6J mice; Lewis lung carcinoma (LLC) was used as an experimental tumor. В. subtilis ІМV В-7724 lectin was administered to tumor-bearing mice or to mice which underwent surgical resection of the primary tumor. The lectin was injected subcutaneously, 10 times, at a single dose of 5 or 1 mg/kg of body weight. The standard indicators of tumor growth and metastasis were evaluated. Results: Independently of the application settings, the lectin at a dose of 1 mg/kg of b.w. caused more pronounced effect than at a dose of 5 mg/kg of b.w. The administration of B. subtilis IMV B-7724 lectin to the mice with LLC in neoadjuvant setting did not cause notable antitumor effect but led to a significant decrease in the number and volume of lung metastases. The lectin administration in adjuvant setting significantly inhibited metastasis: the metastasis inhibition index reached 63.0% and 100% in the mice treated with the lectin at a dose of 5 mg/kg and 1 mg/kg respectively. The mean survival time of the treated animals significantly increased. Conclusion: A pronounced antimetastatic effect of B. subtilis IMV B-7724 lectin administered in an adjuvant setting was demonstrated.

References

Gupta A. Emerging applications of lectins in cancer detection and biomedicine. Materials Today: Proceedings 2020; 31: 651–61. https://doi.org/10.1016/j.matpr.2020.05.810

Siebert G, Jesse P, Laengier A, et al. Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett 2008; 264: 218–28. https://doi.org/10.1016/j.canlet.2008.01.036.

Mbae KM, Umesha S, Manukumar HM. Therapeutic properties of lectins in herbal supplements. Phytochem Rev 2018; 17: 627–43. https://doi.org/10.1007/s11101-018-9572-2

Mazalovska M, Kouokam JC. Plant-derived lectins as potential cancer therapeutics and diagnostic tools. Biomed Res Int 2020; 1631394. https://doi.org/10.1155/2020/1631394

Singh RS, Walia AK. Microbial lectins and their prospective mitogenic potential. Crit Rev Microbiol 2013; 40: 329–47. https://doi.org/10.3109/1040841X.2012.733680

Podgorskii VS, Kovalenko EA, Karpova IS, et al. Extracellular lectin from saprophytic strains of bacteria of the genus Bacillus. Prikladnaia Biokhim i Mikrobiol 2014; 50: 256–63 (in Russian). https://doi.org/10.1134/S0003683814030120

Fedosova NI, Cheremshenko NL, Hetman KI, et al. Physicochemical and cytotoxicity properties of Bacillus subtilis ІМВВ-7724 extracellular lectin. Mikrobiol Z 2021; 83: 39–48. https://doi.org/10.15407/microbiolj83.01.039

Chumak AV, Fedosova NI, Cheremshenko NL, et al. The evaluation of anti-tumor properties of B. subtilis IMV B-7724 lectin in vivo studies. Оncologiya 2022; 24: 31–6. https://doi.org/10.32471/oncology.2663-7928.t-24-1-2022-g.10306

European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes ETS 123. Protection of Vertebrate Animals, 18.III.1986. 48. https://norecopa.no/media/2iydns5h/ets-123-original.pdf

Preclinical studies of drugs. Stefanov OV, ed. Kyiv: Avitsena, 2001. 528 p. (in Ukrainian).

Sidenko AB, Vishnyakov VV, Isaev SM. Theory of Statistics. М: MAX-Press, 2011. 343 p. (in Russian).

Fedosova NI, Karaman OM, Voeykova IM, et al. Comparison of the efficacy of different schedules of application of xenogeneic cancer vaccine on models of metastatic tumor growth. Oncologiya 2017; 19: 145–50 (in Ukrainian).

Symchych TV, Fedosova NI, Karaman OM, et al. The effects of early postoperative immunization with xenogeneic embryo proteins on Lewis lung carcinoma model. Exp Oncol 2018; 40: 275–81.

Kraśko JA, Žilionytė K, Darinskas A, et al. Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model. Oncol Lett 2018; 15: 5098–104. https://doi.org/10.3892/ol.2018.7950

Pryme IF, Bardocz S, Pusztai A, Ewen SWB. Suppression of growth of tumour cell lines in vitro and tumours in vivo by Mistletoe lectins. Histol Histopathol 2006; 21: 285–99. https://doi.org/10.14670/HH-21.285

Chumak A, Shcherbina V, Fedosova N, Chekhun V. Polarization of macrophages of mice under the influence of lectin from Bacillus subtilis IMB B-7724. EUREKA: Life Sciences 2021; 3: 3–10. https://doi.org/10.21303/2504-5695.2021.001878

Magalhães A, Duarte HO, Reis CA. Aberrant glycosylation in cancer: a novel molecular mechanism controlling metastasis. Cancer Cell 2017; 31: 733–5. https://doi.org/10.1016/j.ccell.2017.05.012

Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer 2021; 124: 76–90. https://doi.org/10.1038/s41416-020-01126-7

Downloads

Published

26.05.2023

How to Cite

Fedosova, N., Symchych, T., Cheremshenko, N., Chumak, A., Koval, E., Karaman, O., & Voyeykova, I. (2023). АNTIMETASTATIC EFFECT OF B. SUBTILIS IMV B-7724 LECTIN OBSERVED IN LEWIS LUNG CARCINOMA MODEL. Experimental Oncology, 46(4), 155–158. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17914

Issue

Section

Short communications